WHAT IS HUMAN CYTOMEGALOVIRUS?
Human cytomegalovirus (HCMV) is classified as a DNA herpesvirus. A recent study showed that the HCMV virion contains not only DNA, but also four species of mRNA, indicating that this virus is more complex than previously believed.
HCMV is a disease of the herpes family that remains in humans for life. CMV can cause damage to the brain. If it reaches the brain and the immune system cannot control it, death can occur within weeks to months. If brain damage is less severe, dementia, confusion, fever and memory problems can occur.
HCMV IN THE JABS
Cytomegalovirus (CMV) 'promoter' DNA is combined with the spike protein in the AstraZeneca and Janssen jabs to heighten immune response.
Cytomegalovirus (CMV) 'promoter' DNA is missing from the AZ ingredients list but appears in the Full Risk Assessment Plan approved by the Australian Office of Gene Technology Registration and in European Medical Association Risk documents
AND THEY'RE ALREADY DEVELOPING CMV VACCINES
Pfizer, Moderna, Merck, Takeda, and are all working on developing a vaccine to protect against CMV.
This begs the question...
IF CMV IS A LIFE-LONG DISEASE, WHY IS CMV DNA IN THE COVID-19 JABS?
Excerpts from documents
Australian Office of Gene Technology Registration
"4.1 The genetic modifications
The GM vaccine was produced by deleting E1 and E3 genes from the ChAd Y25 genome and by replacing the E4 region open reading frame (Orf)4, Orf6 and Orf6/7 genes with equivalent genes from HAdV-5 (Dicks et al., 2012). This results in a replication defective GMO which produces more virus during manufacture. In addition, a construct containing a human cytomegalovirus (CMV) promoter driving a codon-optimised full length SARS-CoV-2 spike gene that has been fused to a human tissue plasminogen activator (tPA) leader sequence was then inserted into the E1 locus (van Doremalen et al., 2020b) to boost induction of an immune response.
EMA Public assessment Report - AZ
"The active substance consists of a recombinant, replication-deficient (E1 and E3 deleted) chimpanzee adenovirus (ChAdOx1) that encodes the SARS-CoV-2 (nCoV-19) spike protein combined with a tissue plasminogen activator (tPA) leader sequence. AZD1222 is propagated in T-REx-293 cells, a derivative of the HEK293 cell line. The expression cassette for the nCoV-19 spike protein fused to the tPA leader uses a modified human cytomegalovirus (CMV) promoter and a bovine growth hormone polyadenylation sequence. The HEK293 cell line is an immortalised cell line of primary human embryonic kidney cells transformed by transfection with sheared human adenovirus serotype 5 (HAdV5). The E1 region (E1A and E1B genes) of HAdV5, is stably integrated into chromosome 19 in HEK293 cells. The expression of the E1 region genes by HEK293 cells and its derivatives e.g. T-REx-293 cell line, allows these cells to be used for the propagation of E1-deleted replication-deficient adenoviruses."
JANSSEN (JOHNSON & JOHNSON)
"The Ad26 vector backbone used for Ad26.COV2.S is identical to the vector
backbone of the Ad26-based vaccines that were tested in the available biodistribution studies. The only difference between the vectors, apart from the encoded antigen transgene, is the insertion of a tetracycline operon (TetO) motif in the cytomegalovirus (CMV) promoter sequence of the transgene expression cassette of Ad26.COV2.S."
PROMOTERS IN VACCINES
"Promoter sequences are DNA sequences that define where transcription of a gene by RNA polymerase begins. Promoter sequences are typically located directly upstream or at the 5' end of the transcription initiation site. RNA polymerase and the necessary transcription factors bind to the promoter sequence and initiate transcription. Promoter sequences define the direction of transcription and indicate which DNA strand will be transcribed; this strand is known as the sense strand.
Many eukaryotic genes have a conserved promoter sequence called the TATA box, located 25 to 35 base pairs upstream of the transcription start site. Transcription factors bind to the TATA box and initiate the formation of the RNA polymerase transcription complex, which promotes transcription."
SOURCE LINKS
ABOUT CMV
1.Cytomegalovirus (CMV) -.doc1
5. Australia Office of Gene Technology Registration (OGTR)
6. AUS OGTR Detailed Risk Assessment - DIR180 http://www.ogtr.gov.au/internet/ogtr/publishing.nsf/Content/dir180/$FILE/Full%20Risk%20Assessment%20and%20Risk%20Management%20Plan.pdf
EU Public Assessment Reports
7. AstraZeneca
8. Janssen (Johnson & Johnson)
9. Tissue plasminogen Activator (tPA)
CMV in Lipid Formulations
Article on Cationic lipids (including DSPC) containing magnetic lipid nano-particles and CMV promoter
"The ability of self-amplifying mRNA to encode multiple antigens was evaluated by Magini et al. Using the nucleoprotein and M1 proteins of influenza virus, and by Brito et al. using the Hg/gL protein complex of human cytomegalovirus (HCMV). Potent T cell responses in addition to protection against viral infection were observed following the immunization of animals. The high levels of antigen expression produced by self-amplifying mRNA are due to their ability to self-amplify within cells."
"LNPs can act as adjuvants by themselves due to their lipid content. Some lipids can induce inflammation and stimulate the immune system"
WHICH PHARMACEUTICAL COMPANIES ARE DEVELOPING CMV JABS
PFIZER
While it may not be a household name, cytomegalovirus (CMV), a member of the herpes virus family, is incredibly common—many people acquire it as toddlers or adolescents, and a majority are infected by adulthood. In most people, CMV is harmless and causes no or few symptoms. However, it can pose a danger to babies infected in the womb along with immunocompromised adults. Roughly one out of every 200 babies are born with congenital CMV each year in the U.S., and 20 percent of those will experience long-term complications. These include vision problems, hearing loss, muscle weakness, developmental delay, and intellectual disability. Immunocompromised adults may have vision loss, inflammation of the brain and digestive system, and pneumonia. Because CMV can be so destructive, scientists have long sought to develop a vaccine to protect against it. This has proven difficult due to the properties of the virus. However, Pfizer scientists are making significant advances in their quest to develop a vaccine against thisdestructive virus.
Monday, January 05, 2015
Acquisition Provides Pfizer with a Preclinical CMV Vaccine Candidate. Pfizer Inc. today announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
ASTRAZENECA
DECEMBER 10, 2019
Global Cytomegalovirus (CMV) Therapeutics Market 2019-2023 | Evolving Opportunities with AstraZeneca and Bausch Health | Technavio
"Technavio has been monitoring the global cytomegalovirus (CMV) therapeutics market and the market is poised to grow by USD 241.63 million during 2019-2023 at a CAGR of almost 5% during the forecast period.
The market is driven by the recurring nature of cytomegalovirus disease. Also, the adoption of mandatory screening tests on newborns is anticipated to further boost the growth of the cytomegalovirus therapeutics market."
MODERNA
MARCH 3 2020
Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study
UPDATED APRIL 2021
Moderna’s mRNA-1647 vaccine candidate is designed to protect against CMV infection
The mRNA-1647 vaccine candidate combines 6 mRNAs in a single vial, which encodes for two antigens on the surface of CMV.